Sigrid Jusélius Senior researcher, Associate Professor (Docent) of biochemistry PI at Faculty of Medicine, University of Helsinki, Finland  Author of 139 peer reviewed articles (cited 4095 times), h-index 39 (web of Science) Chair of the Biobio Society and Finnish National Committee for Biosciences Orcid ID: orcid.org/0000-0003-0926-3109 I have a title of docent (associate professor) of biochemistry and since 2009 have been a PI in the Faculty of Medicine, Univ. of Helsinki. After receiving my D.Sc. degree in 2000, I worked for two years as a Marie Curie Industrial Host fellow at GlaxoSmithKline, UK. From 2004 I have worked at the Dept of Clinical Chemistry and Haematology, Univ. of Helsinki, which includes a five-year period as an Academy Research Fellow. Currently I work as a Sigrid Jusélius senior researcher, allowing me to concentrate on research projects. In my doctoral thesis I identified diverse tissue specific glycoforms of glycodelin. Our findings demonstrated that the glycodelin represents one of the foremost examples of how glycosylation dictates the function of a glycoprotein. More recently my group went on to show that glycodelin is differentially glycosylated in endometrial cancer cells and it differentiates these cells towards a less aggressive phenotype, resulting in reduced tumor growth in a preclinical animal model. For the last 20 years my main focus has been on the functions and diagnostic potential of proteases in cancer, especially prostate cancer. These studies involve development of novel patient-derived cell/tissue models to better recapitulate prostate cancer. In an international collaborative effort, which I coordinated, we developed PSA stimulators and KLK2 inhibitors, aiming to slow down prostate cancer growth. Currently my group and collaborators are developing trypsin-3 inhibitors for targeting cancer metastasis. My work has been published in journals like Nature Chemical Biology, Endocrine Reviews, Journal of Clinical Investigation, Blood, Cancer Research and Environmental Health Perspectives. In addition to basic research experience, I have research experience in pharmaceutical industry from my postdoctoral period at GlaxoSmithKline, UK. This exposure to the drug discovery process will be helpful when research innovations are translated to the benefit of patients. Education of postgraduate students including supervision of PhD projects and organization of student seminars and international symposia have been an integral part of my academic life.  I feel that scientists have the responsibility to communicate science to a wider audience. For that purpose, I have taken on the role of Chairman of the Biobio-society. I am also the Chairman of the Finnish National Committee for Biosciences, which presents Finnish biosciences internationally.

Biobio Junior Section, part of the Finnish Biochemical, Biophysical and Microbiological Society (Biobio Society), was set up in 2024 to support the career development and networking opportunities of students and junior researchers in the biosciences in Finland. The Biobio Junior Section organizes its own activities with the support of the Biobio Society and is linked to a wider junior researcher community via the FEBS Junior Section. To find out more about the Biobio Junior Section read their overview post and check the 'Popular contributions' section below. 

Dr. Isabel Varela-Nieto graduated and earned her doctorate in Chemistry, Biochemistry Section, at the University Complutense of Madrid (Spain). She has been a visiting guest scientist at the Medical Schools of Uppsala (FEBS Fellow, Sweden) and San Diego (MEC Sabbatical, USA). She is Professor of Research at the CSIC and group leader at the CIBER of rare diseases (CIBERER, ISCIII) in Madrid. From the early 1990s she has been studying hearing neurobiology and IGF-1 actions. She was the first Chair of the SEBBM Science for Society working group with which she actively collaborates, and member of the FEBS Network working group. She is currently the president of the SEBBM, a member of the FEBS Science and Society Committee and of the ISC Finances Committee.

iam graduated from faculty of science, chemistry and biochemistry dep. i have a biomedical analysis diploma. my master degree focused in treatment diabetes with the combination therapy using natural products and a pharmaceutical. i hope to find a PHD position in biochemistry. mainly my interest in biochemistry. title of thesis( treatment of HFD induced diabetes with combination of metformin and natural products)

Subham Preetam is the Founder & CEO of N BASE. He is a professional biotechnologist in the field of biorobotics, cancer, immunity, biomedical, and nanometerial research. He is dedicated to the advancement of precision medicine and successful preclinical research to enhance the quality of life for individuals. With extensive cross-disciplinary training and experience in translational research, he is currently focused on various research topics, including microrobotics, soft bio-hybrid robots, and quantum nanoparticles for drug delivery. Furthermore, he is involved in developing a bio-fluidics nanomedicine system that leverages the latest drug delivery technologies to create personalized solutions for brain cancer. 

The Hungarian Biochemical Society (HBS) is one of the eight founding members of FEBS. The aim of HBS is to support the work of Hungarian biochemists, molecular biologists and biotechnologists to increase the quality of research and education in molecular life sciences in the frame of universities and research centers of the Hungarian Academy of Sciences. From the beginnings, HBS hosts regular meetings, methodological presentations and workshops, including three FEBS3+ conferences jointly organized with the Slovenian, Croatian and Serbian Societies. These provide the first opportunities for young researchers to present and critically discuss their results and to establish new professional relationships. HBS publishes the quarterly journal “Biokémia” including news and events of the Society, international scientific social issues, historical reviews and scientific publications. For over five decades, HBS significantly contributed to the work of FEBS committees and the editorial offices of its Journals and organized the 9th and 20th FEBS Meetings (1974, 1990) and the 30th FEBS Congress-9th IUBMB Conference (2015) in Budapest.